Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Posts Earnings Results

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) announced its earnings results on Friday. The company reported ($0.02) earnings per share (EPS) for the quarter, FiscalAI reports.

Oaktree Acquisition Corp. III Life Sciences Stock Up 0.1%

Shares of NASDAQ OACC traded up $0.01 during mid-day trading on Friday, reaching $10.71. The company had a trading volume of 825 shares, compared to its average volume of 5,153. The business’s 50-day simple moving average is $10.74 and its 200 day simple moving average is $10.70. Oaktree Acquisition Corp. III Life Sciences has a one year low of $10.50 and a one year high of $10.93.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Oaktree Acquisition Corp. III Life Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.

Institutional Investors Weigh In On Oaktree Acquisition Corp. III Life Sciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Periscope Capital Inc. bought a new position in Oaktree Acquisition Corp. III Life Sciences in the 3rd quarter valued at about $3,488,000. DLD Asset Management LP raised its position in shares of Oaktree Acquisition Corp. III Life Sciences by 0.9% in the 1st quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock valued at $1,447,000 after buying an additional 1,200 shares in the last quarter. Finally, Rangeley Capital LLC raised its position in shares of Oaktree Acquisition Corp. III Life Sciences by 52.8% in the 1st quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock valued at $647,000 after buying an additional 21,156 shares in the last quarter.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company (SPAC) formed to pursue a business combination with a company in the life sciences sector. Its potential transactions could include a merger, acquisition, or similar combination. The company was sponsored by Oaktree Capital Management. As a SPAC, it did not have its own operating business or sell products and services; its intended role was to identify and combine with a business in its target sector.